EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry

Santosh B Murthy iD, Cenai Zhang iD, Shreyansh Shah iD, Lee H Schwamm iD, Gregg C Fonarow iD, Eric E Smith iD, Deepak L Bhatt iD, Wendy C Ziai iD, Hooman Kamel iD, Kevin N Sheth

Stroke · 2023

DOI: 10.1161/strokeaha.123.043194 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Stroke, 2023. Verfasst von Santosh B Murthy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute (S.B.M., C.Z., H.K.), Weill Cornell Medicine, New York, N…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Survivors of intracerebral hemorrhage (ICH) face an increased risk of ischemic cardiovascular events. Current ICH guidelines do not provide definitive recommendations regarding the use of antithrombotic and statin therapies. We, therefore, sought to study practice patterns and factors associated with the use of such medications after ICH. METHODS: This was a cross-sectional study of patients with ICH in the Get With The Guidelines-Stroke registry, between 2011 and 2021. Patients transferred to another hospital, those who died during hospitalization, and those with missing information on discharge medications were excluded. The study exposure was the proportion of patients who were prescribed antithrombotic or statin medications. We first ascertained the proportion of patients prescribed antithrombotic and lipid-lowering medications at discharge overall and across strata defined by pre-ICH use and history of previous ischemic vascular disease or atrial fibrillation. We then studied factors associated with the discharge prescription of these medications after ICH, using multiple logistic regressions. RESULTS: In the final cohort, 50 416 (10.4%) of 486 586 patients with ICH were prescribed antiplatelet medications, 173 322 (35.1%) of 493 491 patients with ICH were prescribed statins, and 27 085 (5.4%) of 486 585 patients with ICH were prescribed anticoagulation therapy at discharge. The proportion of patients with antiplatelet therapy was 16.6% with pre-ICH use and 15.6% in those with previous ischemic vascular disease. Statins were prescribed to 41.1% and 43.7% of patients on previous lipid-lowering therapy and ischemic vascular disease, respectively. Anticoagulation therapy was restarted in 11.1% of patients. In logistic regression analysis, factors associated with higher use of antithrombotic or statin therapies after ICH were younger age, male sex, pre-ICH medication use, previous ischemic vascular disease, atrial fibrillation, lower admission National Institutes of Health Stroke Scale, longer length of stay, and favorable discharge outcome. CONCLUSIONS: Few patients with ICH are prescribed antithrombotic or statin therapies at hospital discharge. Given the emerging association between ICH and future major cardiovascular events, trials examining the net benefit of antiplatelet and lipid-lowering therapy after ICH are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtrial FibrillationStrokeHumansMaleFibrinolytic AgentsCross-Sectional StudiesAnticoagulantsCerebral HemorrhageRegistriesLipidsRisk Factors

Stichwörter der Autor:innen

anticoagulantsatrial fibrillationischemic strokelipidsstroke

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsFibrinolytic AgentsAnticoagulantsLipids

Autor:innen und Institutionen

  • Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute (S.B.M., C.Z., H.K.), Weill Cornell Medicine, New York, NY.
  • Department of Neurology (S.B.M., C.Z., H.K.), Weill Cornell Medicine, New York, NY.
  • Department of Neurology, Duke University Hospital, Durham, NC (S.S.).
  • Department of Biomedical Informatics and Data Sciences (L.H.S.), Yale School of Medicine, New Haven, CT.
  • Division of Cardiology, Ronald Reagan University of California, Los Angeles Medical Center (G.C.F.).
  • Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, AB, Canada (E.E.S.).

ORCID-Profile: Santosh B Murthy, Cenai Zhang, Shreyansh Shah, Lee H Schwamm, Gregg C Fonarow, Eric E Smith, Deepak L Bhatt, Wendy C Ziai, Hooman Kamel

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Murthy, S. B., Zhang, C., Shah, S., Schwamm, L. H., Fonarow, G. C., Smith, E. E., Bhatt, D. L., Ziai, W. C., Kamel, H., & Sheth, K. N. (2023). Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry. Stroke. https://doi.org/10.1161/strokeaha.123.043194

Vancouver

Murthy SB, Zhang C, Shah S, Schwamm LH, Fonarow GC, Smith EE, et al. Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry. Stroke. 2023. doi:10.1161/strokeaha.123.043194

BibTeX
@article{Murthy2023,
  author = {Murthy, Santosh B and Zhang, Cenai and Shah, Shreyansh and Schwamm, Lee H and Fonarow, Gregg C and Smith, Eric E and Bhatt, Deepak L and Ziai, Wendy C and Kamel, Hooman and Sheth, Kevin N},
  title = {Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry},
  journal = {Stroke},
  year = {2023},
  doi = {10.1161/strokeaha.123.043194}
}
Kostenlos starten →